EC Clears Eculizumab (Soliris) for Neuromyelitis Optica

Share this post

Eculizumab is now indicated in Europe for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 (AQP4) antibody-positive and whose disease is following a relapsing course.
International Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply